Indegene recognized as GenAI leader in life sciences by Everest Group

Published 11/02/2025, 15:18
Indegene recognized as GenAI leader in life sciences by Everest Group

Investing.com -- Everest Group, a prominent global research and consulting firm, has identified Indegene as a leading player in the adoption of generative AI (GenAI) within the life sciences sector. In their report titled ’AI-deas to Action (WA:ACT): Operationalizing Generative AI in Life Sciences’, the Everest Group recognized the comprehensive GenAI capabilities of Indegene, which encompass scale, range of use cases, strategic collaborations, and value provided to clients.

The report emphasized that Indegene’s comprehensive GenAI strategy and enterprise-grade, ready-for-production solutions are assisting life sciences companies in optimizing operations and achieving substantial productivity enhancements across multiple use cases. These use cases cover the clinical, medical, and commercial aspects of the life sciences value chain.

Tarun Mathur, CTO of Indegene, commented on the recognition, stating, “We believe GenAI is a generational opportunity for life sciences leaders to make the strategic leap and drive transformational business impact. We are helping them maximize GenAI’s potential - solve real business challenges, prioritize use cases that deliver clear business outcomes, and realize benefits in a responsible and compliant way.”

The Everest Group evaluated each service provider’s GenAI capabilities based on four specific parameters: scale, focusing on revenue, client reach and pipeline; the quality and impact of industry-specific use cases across the value chain either in pilot or production stages; the nature of strategic partnerships across the board and the capability boost thereof; and the amount of real, measurable value realized by clients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.